CagriSema vs Tirzepatide: REDEFINE 4 Head-to-Head Results Explained

CagriSema is not yet on the market. It is the most important GLP-1-adjacent drug in the pipeline — and the one whose head-to-head data against tirzepatide has generated the most discussion about what "better" and "non-inferior" actually mean.

Here is what the trial showed, what the amylin mechanism adds, and how to think about CagriSema versus current options once it becomes available.

What CagriSema is

CagriSema is a fixed-dose combination drug:

• Semaglutide 2.4 mg — the same GLP-1 component as Wegovy (obesity label) at its standard maintenance dose
• Cagrilintide 2.4 mg — a long-acting amylin analog, not a GLP-1

Both components are injected once weekly in a single combined injection. Novo Nordisk filed the NDA with the FDA on December 18, 2025. An FDA decision is expected in late 2026 or early 2027.

Why pair amylin with a GLP-1? Amylin is co-secreted with insulin from pancreatic beta cells and acts on amylin and calcitonin receptors in the brainstem and hypothalamus — distinct from GLP-1 receptors. It contributes to post-meal satiety, slows gastric emptying, and suppresses glucagon. Combining GLP-1 agonism with an amylin analog means targeting two independent receptor systems that both contribute to satiety, potentially producing additive effects that neither achieves alone.

This is conceptually different from tirzepatide, which pairs GLP-1 with GIP (targeting insulin sensitivity and fat metabolism) versus CagriSema, which pairs GLP-1 with amylin (targeting a different satiety pathway from the brainstem).

REDEFINE trial data

REDEFINE 4 was the direct head-to-head — the trial that generated the most attention. 1,027 participants with obesity and without T2D, randomised to CagriSema or tirzepatide 15 mg for 84 weeks.

CagriSema: 23.0%
Tirzepatide 15 mg: 25.5%

The difference: 2.5 percentage points. CagriSema did not meet its pre-specified non-inferiority margin of 3.2 percentage points.

What non-inferiority means (and doesn't mean)

Non-inferiority is a specific statistical concept. Novo Nordisk pre-specified that CagriSema would be declared non-inferior to tirzepatide if the lower bound of the confidence interval for the difference in weight loss was within 3.2 percentage points. The actual gap (2.5 points) was outside that margin.

This means: CagriSema cannot be statistically claimed to be as effective as tirzepatide based on this trial's design.

This does not mean: CagriSema "failed," or that 23% weight loss is a poor outcome.

For context: SURMOUNT-1 (the pivotal tirzepatide trial) showed approximately 20.9% mean weight loss at 72 weeks at the 15 mg dose. CagriSema's 23% in REDEFINE 4 would have been competitive with tirzepatide's own pivotal data — just not with tirzepatide in a head-to-head where both groups were measured at the same time under the same conditions.

The more precise statement: tirzepatide produced more weight loss than CagriSema in this specific trial, at the maximum approved tirzepatide dose, over 84 weeks. The difference is real. It is also 2.5 percentage points.

How the mechanisms compare

For T2D patients where insulin sensitivity and A1C control are priorities, tirzepatide's GIP mechanism has advantages not replicated by CagriSema's amylin component. For patients focused purely on weight loss, the 23% vs 25.5% question is the relevant comparison.

The competitive picture after CagriSema approval

If CagriSema is approved in late 2026 / early 2027, it will enter a market where:

• Tirzepatide (Zepbound at 15 mg + HD): 25.5% weight loss in head-to-head
• Wegovy HD (7.2 mg semaglutide): approximately 19% in STEP UP, approved March 2026
• CagriSema (pending): 23% in REDEFINE 4

CagriSema would slot above Wegovy HD and below tirzepatide on efficacy. Its amylin mechanism is clinically distinct, meaning some patients who do not respond fully to GLP-1 monotherapy might respond differently to the GLP-1 + amylin combination — an effect that population averages do not capture.

For patients already on Wegovy who want to step up before CagriSema approval, Wegovy HD is the available escalation. For the full pipeline picture, see CagriSema — NDA status and what to know.

What this means if you are making a treatment decision now

CagriSema is not yet available. No one is on it. The relevant comparison is still tirzepatide vs semaglutide — and for the most effective currently available option, tirzepatide produces more weight loss than semaglutide at equivalent doses across all major comparison data.

The comparison articles for current options: Wegovy vs Zepbound, Ozempic vs Mounjaro. When CagriSema approval status changes, this page will be updated.